Milnacipran. A review of its use in depression

Drugs

Volumn 56, Issue 3, 1998, Pages 405-427

  Spencer, Caroline M ^a   Wilde, Michelle I ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; MILNACIPRAN; NORADRENALIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANTICHOLINERGIC EFFECT; ANXIETY; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DYSPNEA; DYSURIA; HEADACHE; HOT FLUSH; HUMAN; INSOMNIA; LONG TERM CARE; META ANALYSIS; NAUSEA; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PEER REVIEW; RELAPSE; REVIEW; SWEATING; TACHYCARDIA; TREMOR; VERTIGO; VOMITING; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOPROPANES; DEPRESSIVE DISORDER; HUMANS;

EID: 0031661167     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856030-00010     Document Type: Review

References (79)

1. Viazzo P, Alphand V, Furstoss R. Microbiological transformations 34: enantioselective hydrolysis of a key-lactone involved in the synthesis of the antidepressant milnacipran®. Tetrahedron Lett 1996; 37 (26): 4519-22
2. Morel C, Charveron M, Finberg JP, et al. Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 1985 Dec; 24: 1211-9
3. Assie M-B, Broadhurst A, Briley M. Is down-regulation of β-adrenoceptors necessary for antidepressant activity? In: Briley M, Fillion G, editors. New concepts in depression. London: Mac Millan Press, 1988: 161-6
4. Assie MB, Charveron M, Palmier C, et al. Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat. Neuropharmacology 1992 Feb; 31: 149-55
5. Matsubara R, Matsubara S, Koyama T, et al. Effect of chronic treatment with milnacipran (TN-912), a novel antidepressant, on beta-adrenergic receptor-adenylate cyclase system and serolonin 2 receptor in the rat cerebral cortex [in Japanese|. Jpn J Neuropsychopharmacol 1993; 15 (2): 119-26
6. Morel C, Briley M. Effect of antidepressant drugs on monoamine synthesis in brain in vivo. Neuropharmacology 1992 Jul; 31: 679-84
7. Kitamura Y, Nagatani T, Takao K, et al. Pharmacological study of milnacipran, a novel antidepressant [in Japanese]. Jpn J Neuropsychopharmacol 1995; 17 (1): 25-34
8. Palmier C, Puozzo C, Lenehan T, et al. Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran. Eur J Clin Pharmacol 1989 Sep; 37: 235-8
9. Moret C, Briley M. Milnacipran, a double noradrenaline and 5-HT reuptake inhibiting antidepressant increases cerebral extracellular monoamine levels [abstract no. P.1.024]. Eur Neuropsychopharmacol 1996 Sep; 6 Suppl. 4: S4-68
10. de Montigny C, Mongeau R, Weiss M, et al. The antidepressant drug milnacipran modulates 5-HT neuron activity via the noradrenergic system [abstract no. 103. 10]. 24th Annual Meeting of the Society of Neuroscience; 1994 Nov 13-18; Florida, USA, 226
11. 3H]milnacipran, a new antidepressant drug, and their relationship to the serotonin transporter in rat brain. Brain Res 1994 Dec 30; 668: 129-43
12. Moret C. Serotonergic autoreceptor and antidepressants [in French]. Psychiatr Psychobiol 1990; 5 (3): 195-9
13. Neliat G, Bodinier M-C, Panconi E, et al. Lack of effect of repeated administration of milnacipran, a double noradrenaline and serotonin reuptake inhibitor, on the β-adrenoceptor-linked adenylate cyclase system in the rat cerebral cortex. Neuropharmacology 1996; 35 (5): 589-93
14. 2-autoreceptor sensitivity. Prog Neuropsychopharmacol Biol Psychiatry 1994 Oct; 18: 1063-72
15. Stenger A, Couzinier J-P, Briley M. Psychopharmacology of midalcipran. 1-phenyl-1-diethyl-amino-carbonyl-2-aminomethyl-cyclopropane hydrochloride (F 2207), a new potential antidepressant. Psychopharmacology Berl 1987; 91: 147-53
16. 1-and β-adrenoceptors in the antagonism of tetrabenazine-induced effects by antidepressants. In: Briley M, Fillion G, editors. New concepts in depression, London: MacMillan Press, 1988: 211-5
17. Bonnaud B, Cousse H, Mouzin G, et al. 1-Aryl-2-(amino-methyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants. J Med Chem 1987 Feb; 30: 318-25
18. Stenger A, Laval J, Couret E, et al. Behavioral changes in mice after acute and chronic imipramine or milnacipran treatment [abstract]. Eur J Pharmacol 1990 Jul 5; 183: 1907
19. Serre C, Elphick M, Grahame-Smith D, et al. Lack of anticholinergic action of midalcipran compared to amitriptyline in normal subjects [abstract no. 32.05.28]. Psychopharmacology 1988; 96 Suppl: 273
20. Hashimoto S, Inoue T, Koyama T. Serotonin reuptake inhibitors reduced conditioned fear stress-induced freezing behavior in rats. Psychopharmacology 1996; 123: 182-6
21. Sasaki N, Nara K, Murata S, et al. In vivo neurochemical effects of milnacipran on forced swimming of the rat [abstract]. Psychiatr Clin Neurosci 1996 Apr. 50: S82
22. Redmond AM, Kelly JP, Leonard BE. The behavioural effects of milnacipran in the olfactory bulbectomised rat model of depression. Med Sci Res 1995 Aug; 23: 533-4
23. Lacroix P, Rocher N, Gandon JM, et al. Antidepressant effects of milnacipran in the learned helplessness test in rats [abstract]. Eur Neuropsychopharmacol 1995 Sep; 5 Spec. Issue: 276
24. Kitayama I, Nomura J. Effect of maprotiline and milnacipran on the spontaneous activity and brain catecholamine of the stress-induced depression-model rats [abstract]. Jpn J Psychiatry Neurol 1994 Sep: 48: 700-1
25. Poirier MF, Galinowski A, Longevialle R, et al. Etude comparative du milnacipran (2) versus placebo sur les fonctions congitives chez des volontaires sains [abstract]. 3éme Conférence Vigilance et Performances Psychomotrices; 1991 Apr 8-9; Annecy, France.
26. Hindmarch I, Orluc A, Serre C. Etude des effets du milnacipran (F 2207) sur les fonctions sensori - et psycho-motrices du volontaires sain age de plus de 60 ans [abstract]. Association Francaise de Psychiatric Biologique; 1989 May 20
27. Hindmarch I, Alford C, Barwell F, et al. Measuring the side effects of psychotropics: the behavioural toxicity of antidepressants. J Psychopharmacol 1992; 6 (2): 198-203
28. Richet F, Marais J, Serre C, et al. Etude comparative en double aveugle milnacipran et placebo avec et sans alcool sur la vigilance et la conduite automobile de volontaires sains [abstruct]. 3éme Conférence Vigilance et Performances Psychomotrices; 1991 Apr 8-9; Annecy, France.
29. Caron J, Libersa C, Hazard JR. et al. Acute electrophysiological effects of intravenous milnacipran, a new antidepressant agent. Eur Neuropsychopharmacol 1993 Dec; 3: 493-500
30. Kawasaki H, Yamamoto R, Urahe M, et al. Electroencephalographic and cardiovascular effects of milnaciplan hydrochloride (TN-912). a novel antidepressant [in Japanese]. Folia Pharmacol Jpn 1991 Nov; 98: 345-55
31. Rouet RH, Tisne-Versailles J, Adamantidis MM, et al. Comparative in vivo andin vitro study of the cardiac effects of midalcipran and imipramine. Fundam Clin Pharmacol 1989; 3: 237-44
32. Puozzo C, Rostin M, Montastruc JL, et al. Absolute biouvailability study of midalcipran (F 2207) in volunteers [abstract]. Third European Congress of Biopharmaceutics and Pharmacokinetics Proceedings; 1987 Apr 21-24; Freiburg, Switzerland.
33. Puozzo C, Filaquier C, Briley M. Plasma levels of F 2207, midalcipran, a novel antidepressant, after single oral administration in volunteers [abstract]. Br J Clin Pharmacol 1985; 20: 291P
34. Retz W, Becker T, Schmidtke A, et al. Multiple and single dose pharmacokinetics ot milnacipran in major depressive patients [abstract]. Eur Neuropsychopharmacol 1995 Sep: 5 Spec. Issue: 296-7
35. 3H)-5HT uptake in platelets after human repeated administration ot midalcipran [abstract]. Acta Pharmacol Toxicol 1986; 59: 214
36. Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 1996 Sep; 11 Suppl. 4: 15-27
37. Takahashi A, Kawaguchi T, Kasahara T, et al. Absorption and excretion study of milnacipran hydrochloride in healthy volunteers, a 15mg tablet. Influence ot food intake and multiple oral administration [in Japanese]. Rinsho Iyaku 1995; 11 (5) Suppl. 3: 119-32
38. Puozzo C, Lambe R, Briley M. Pharmacokinetic-pharmacodynamic relationship of milnacipran on platelet uptake model [abstract]. Eur Neuropsychopharmacol 1996 Apr; 6 Suppl. 1: S17
39. Puozzo C, Albin H, Vincon G, et al. Pharmacokinetics of milnacipran in liver impairment [abstract]. Eur J Drug Metab Pharmacokinet 1996; 21 (2) Suppl.: 77
40. 14C-F 2207: a quantitative whole-body autoradiographic study. In: Baillie TA, Jones JR, editors. Synthesis and applications of isotopically labelled compounds. Proceedings of the Third International Symposium: 1988 Jul 17-21; Innsbruck, Austria. Amsterdam: Elsevier Science Publishers BV, 1988:637-40
41. Puozzo C, Pozet N, Deprez D, et al. Pharmacokinetics of milnacipran in renal impairment [abstract]. Eur J Drug Metab Pharmacokinet 1996; 21 (2) Suppl.: 78
42. Puozzo C, Deville G, Bromet-Petit M, et al. Single cluse pharmacokinctics fo F 2207, a new antidepressant drug, in elderly volunteers [abstract]. Symposium on variability in pharmacokinetics und drug response; 1988 Oct 3-5; Gothenburg, Sweden.
43. Ansseau M, von Frenekell R, Serre C. Pilot study of milnacipran in panic disorder. Eur Psychiatry 1941; 6 (2): 103-5
44. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., Washington, DC: American Psychiatric Association, 1980.
45. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed revised. Washington DC: American Psychiatric Association, 1987.
46. Hamilton M. Development of a rating scale for primary depressive illness. Brit J Soc Clin Psychol 1967; 6: 278-96
47. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9
48. Lecrubier Y, Pletan Y, Solles A, et al. Clinical efficacy of milnacipran: placebo-controlled trials. Int Clin Psychopharmacol 1996 Sep; 11 Suppl. 4: 29-33
49. Serre C, Clerc G, Escande M, et al. An early clinical trial of midalcipran, I-phenyl-1-diethyl aminocarbonyl 2-aminomethyl cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant. Curr Ther Res Clin Exp 1986; 39 (1): 156-64
50. Ansseau M, von Frenckell R, Mertens C, et al. Controlled comparison of two doses of milnacipran (F 2207) and amitripty-line in major depressive inpatients. Psychopharmacology Berl 1989; 98: 163-8
51. Kawakatsu S, Totsuka S, Yoshimura E, et al. Clinical effectiveness of milnacipran hydrochloride by long-term administration study [in Japanese]. Rinsho Iyaku 1994; 10 (12): 2715-36
52. Macher J-P, Sichel J-P., Serre C, et al. Double-blind placebocontrolled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 1989; 22 (2): 77-82
53. Puech A, Montgomery SA, Prost JF, et al. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997; 12: 99-108
54. Yamashita I, Matsubara R, Onodera I, et al. Clinical evaluation of milnacipran hydrochloride (TN-912) on depression and depressive states. Phase III clinical trial with imipramine hydrochloride as a control drug [in Japanese]. Rinsho Iyaku 1995; 11 (4) 819-42
55. Ansseau M, Papart P, Troisfontaines B, et al. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology 1994 Feb; 114: 131-7
56. Clerc G, Pagot R, Bouchard JM, et al. Therapeutic contribution of milnacipran and clomipramine during a 3-month treatment: results of a comparative study [in French). Psychiatr Psychobiol 1990; 5 (2): 137-43
57. Kasper S, Pletan Y, Solles A, et al. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol 1996 Sep; II Suppl. 4: 35-9
58. Steen A, Den Boer JA. A double-blind six months comparative sludy of milnacipran and clomipramine in major depressive disorder. Int Clin Psychopharmacol 1997; 12: 269-81
59. Leinonen E, Lepola U, Koponen H, et al. Long-term efficacy and safely of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand 1997 Dec; 96: 497-504
60. Ansseau M, von Frenckell R, Gerard M-A, et al. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine. Eur Neuropsychopharmacol 1991 May; 1: 113-21
61. Ansseau M, von Frenckell R, Papart P, et al. Controlled comparison of milnacipran (F2207) 200 mg and amitriptyline in endogenous depressive inpatients. Hum Psychopharmacol 1989; 4 (3): 221-7
62. Matsubara R, Onodera I, Ito K, et al. A double-blind comparison of milnacipran and imipramine in depressive patients [abstract]. Eur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 48
63. Ferreri M. A double-blind comparison of the antidepressant actions of milnacipran and imipramine in major depressive disorder. Institut de Recherche Pierre Fabre, 1997. (Data on file).
64. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. Institut de Recherche Pierre Fabre, 1997. (Data on file).
65. Tignol J, Pujol-Domenech J, Chartres JP, et al. Double-blind study of the efficacy and safety of milnacipran (100 mg/day) and imipramine (100 mg/day) in elderly patents with major depressive episode. Acta Psychiatr Scand 1998; 97: 157-65
66. Lopez-Ibor J, Guelfi JD, Pletan Y, et al. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 1996 Sep; 11 Suppl. 4: 41-6
67. Guelfi J-D, Ansseau M, Corruble E, et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in severely depressed inpatients. Institut de Recherche Pierre Fabre, 1997. (Data on file).
68. Endo S, Miura S, Murasaki M, et al. Clinical evaluation of milnacipran hydrochloride, a new antidepressant for depression and depressive state. Phase III clinical trial with mianserin hydrochloride as a control drug [in Japanese]. Rinsho Hyoka 1995; 23 (1): 39-64
69. Montgomery SA, Prost JF, Solles A, et al. Efficacy and tolerability of milnacipran: an overview. Int Clin Psychopharmacol 1996 Sep; 11 Suppl. 4: 47-51
70. Yamashita I, Onodera I, Ito K, et al. Clinical evaluation of TN-912 (milnacipran hydrochloride), a fourth generation antidepressant, in the late phase II study (dose finding study) [in Japanese]. Rinsho Iyaku 1994; 10 (11): 2445-71
71. Tsutsui S, Nakano K, Tsuboi K, et al. Clinical effect of milnacipran hydrochloride (TN-912), a new antidepressant, in the field of psychosomatic medicine [in Japanese). Rinsho Iyaku 1994: 10 (11): 2473-88
72. Takahashi A, Murasaki M, Inami M, et al. Clinical utility of examination of milnacipran hydrochloride, a new antidepressant in the elderly [in Japanese]. Rinsho Iyaku 1995; 11 (5) Suppl. 3: 103-18
73. Pierre Fabre Medicament. Ixel 50mg antidepressant: SNRI serotonin and noradrenaline reuptake inhibitor. Boulogne: Pierre Fabre Medicament C.N.S. line, 1997. (Data on file).
74. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med 1994 Dec 19; 97 Suppl. 6A: 24S-32S
75. Hirschfeld RMA, Schatzberg AF. Long-term management of depression. Am J Med 1994 Dec 19; 97 Suppl. 6A: 33S-8S
76. McFarland BH. Cost-effectiveness considerations for managed care systems: treating depression in primary care. Am J Med 1994 Dec 19; 97 Suppl. 6A: 47S-58S
77. Leonard BE. Mechanisms of action of antidepressants. CNS Drugs 1995; 4 Suppl. 1: 1-12
78. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994; 8(4): 238-49
79. Briley M, Prost JF, Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 1996 Sep; 11 Suppl. 4: 10-4